Overcoming Patient Barriers to Optimal Diabetes Care: Perspectives for Managed Care
Overcoming Patient Barriers to Optimal Diabetes Care: Perspectives for Managed Care
On-Demand Webcast
Presenters/Q&A Cohosts
Mary Barton, MD, MPP
Vice President, Performance Measurement
National Committee for Quality Assurance
Washington, DC
William J. Cardarelli, PharmD
Director of Pharmacy
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts
Edward Shahady, MD
Course Director, Primary Care Cardiometabolic Risk Summit
Editorial Board Member, Consultant
President for Medicine NF SG Chapter ADA
Medical Director, Diabetes Master Clinician Program FAFP/F
Fernandina Beach, Florida
Learning Objectives
After completing this activity, participants should be able to:
- Outline patient- and provider-related barriers that contribute to suboptimal and costly type 2 diabetes care
- Implement strategies to overcome patient- and provider-related barriers to type 2 diabetes care, previously perceived outside of managed care’s scope
- Apply recent evidence on current and emerging type 2 diabetes pharmacotherapies to formulary discussions and review
- Develop or augment a type 2 diabetes disease management program, based on available resources, such as the NCQA Diabetes Recognition Program, current guidelines, and Comprehensive Diabetes Care HEDIS performance measure
Intended Learners
This activity is designed for managed markets physicians and pharmacists.
Activity Overview
This on-demand webcast is available with synchronized slides and audio.
To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
There is no fee associated with this activity.
This educational activity is a knowledge-based activity.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for these enduring materials.
Release Date: January 9, 2013
Expiration Date: January 9, 2014
Estimated time to complete: 1 hour
For questions regarding this educational activity, please call 609-371-1137.
Hardware/Software Requirements
All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
Accreditation
In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Accreditation
NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Accreditation
This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (0276-9999-12-053-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Director, Accreditation Services, NACCME, may be made for a second level of review.
Independent Clinical Reviewer: Frank Lavernia, MD, Founder and Director, North Broward Diabetes Center, Pompano Beach, Florida
Planning Committee
The planning committee comprises Mary Barton, MD, MPP, William J. Cardarelli, PharmD, Frank Lavernia, MD, and Edward Shahady, MD; and Stephen Chavez, Lindsay Halverson, Mike Kearney, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Barton: Disclosure information will be provided in the activity materials.
Dr. Lavernia: Advisory board—Sanofi; Promotional speakers' bureau—Abbott Pharmaceuticals, Novo Nordisk
Dr. Shahady: Consultant—Merck; Promotional speakers bureau—Merck; Advisory committee—Amylin, Novo Nordisk, Sanofi
Dr. Cardarelli disclosed no relevant financial relationships with any commercial interests.
Mr. Chavez, Ms. Halverson, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.
Mr. Kearney: Stock Shareholder – Savient Pharmaceuticals, Inc.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty have disclosed that the following off -label/unapproved uses of drugs and/or devices will be discussed: the investigational use of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 agonists.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Grant Support
Supported by an educational grant from Lilly USA, LLC
Jointly sponsored by North American Center for Continuing Medical Education, LLC and National Committee for Quality Assurance
